Michelangelo Fiorentino

Diagnostic performance of MRI/TRUS fusion-guided biopsies vs. systematic prostate biopsies in biopsy-naïve, previous negative biopsy patients and men undergoing active surveillance.

Borghesi M, Bianchi L, Barbaresi U, Vagnoni V, Corcioni B, Gaudiano C, Fiorentino M, Giunchi F, Chessa F, Garofalo M, Bertaccini A, Angelini S, Ercolino A, Casablanca C, Droghetti M, Golfieri R, Schiavina R.

Minerva Urol Nephrol. 2021 Mar 26. PMID: 33769008

Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience.

Rizzo A, Mollica V, Giunchi F, Dall'Olio FG, Rosellini M, Marchetti A, Franceschini T, Schiavina R, Brunocilla E, Fiorentino M, Ardizzoni A, Massari F.

Pathol Res Pract. 2021 Apr. 220:153410. PMID: 33765474

Interchangeability of light and virtual microscopy for histopathological evaluation of prostate cancer.

Zelic R, Giunchi F, Lianas L, Mascia C, Zanetti G, Andrén O, Fridfeldt J, Carlsson J, Davidsson S, Molinaro L, Vincent PH, Richiardi L, Akre O, Fiorentino M, Pettersson A.

Sci Rep. 2021 Feb 05. 11(1):3257. PMID: 33547336

Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing.

Mollica V, Franceschini T, Gruppioni E, Rizzo A, Ricci C, Schiavina R, Brunocilla E, Ardizzoni A, Fiorentino M, Giunchi F, Massari F.

Pathol Res Pract. 2021 Mar. 219:153350. PMID: 33556910

Renal Tumors with Oncocytic and Papillary Features: A Phenotypic and Genotypic Study.

Franceschini T, Giunchi F, Mollica V, Altimari A, Capizzi E, Banfi M, Schiavina R, Fiorentino M, Massari F.

Diagnostics (Basel). 2021 Jan 28. 11(2). PMID: 33525402

Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer.

Pernar CH, Parmigiani G, Giovannucci EL, Rimm EB, Tyekucheva S, Loda M, Finn SP, Heiden MGV, Fiorentino M, Ebot EM, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2021 Apr. 30(4):751-756. PMID: 33500320

Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study.

Mollica V, Rizzo A, Tassinari E, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Ardizzoni A, Massari F.

Anticancer Drugs. 2021 01 01. 32(1):74-81. PMID: 33290315

Pathological features and outcomes of incidental renal cell carcinoma in candidate solid organ donors.

Ambrosi F, Ricci C, Malvi D, Cillia C, Ravaioli M, Fiorentino M, Cardillo M, Vasuri F, D'Errico A.

Kidney Res Clin Pract. 2020 Dec 31. 39(4):487-494. PMID: 32855366

Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers.

Giunchi F, Massari F, Altimari A, Gruppioni E, Nobili E, Fiorentino M, Ardizzoni A.

Diagnostics (Basel). 2020 Dec 20. 10(12). PMID: 33419298

Reliability of programmed death ligand 1 (PD-L1) tumor proportion score (TPS) on cytological smears in advanced non-small cell lung cancer: a prospective validation study.

Ricci C, Capizzi E, Giunchi F, Casolari L, Gelsomino F, Rihawi K, Natali F, Livi V, Trisolini R, Fiorentino M, Ardizzoni A.

Ther Adv Med Oncol. 2020. 12:1758835920954802. PMID: 33299472